## 1 Title: Effectiveness of mHealth Interventions for Blood Pressure

## 2 Control among Vulnerable Populations: A Systematic Review

- 3 Kristen M.J. Azar, RN, MSN/MPH,<sup>1, 2</sup> Yael Zoken, BS,<sup>3</sup> Rhonda M. Cooper-DeHoff,
- 4 Pharm.D, MS,<sup>4</sup> Valy Fontil, MD, MAS, MPH,<sup>5</sup> Madelaine, F. Modrow,<sup>5</sup> Catherine Nasrallah,
- 5 MPH, CHES,<sup>6</sup> Mark J. Pletcher, MD, MPH<sup>5</sup>
- 6 <sup>1</sup>Sutter Health-Center for Health Systems Research (CHSR)
- <sup>7</sup> <sup>2</sup>Sutter Health- Institute for Advancing Health Equity (IAHE)
- 8 <sup>3</sup>Sackler School of Medicine, New York
- 9 <sup>4</sup>University of Florida, College of Pharmacy
- 10 <sup>5</sup>University of California, San Francisco, School of Medicine (UCSF)
- <sup>6</sup>University of California, San Francisco, Department of Medicine (UCSF)
- 12 Corresponding author: Kristen M.J. Azar, RN, MSN/MPH; <u>azark@sutterhealth.org</u>

13

**14 Word Count:** 4,253

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 15 Abstract

- 16 Social determinants of health and sociodemographic differences place some individuals at
- 17 higher risk for hypertension leading to persisting disparities. While mobile health (mHealth)
- 18 offers a promising approach to facilitate blood pressure (BP) management, it remains unclear
- 19 which interventions are most effective for addressing disparities in hypertension control. We
- 20 reviewed the current literature to examine whether mHealth interventions for BP control are
- effective in improving BP control in populations vulnerable to disparities in hypertension.
- 22 We conducted a systematic review using multiple databases from January 1, 2009 through
- 23 December 31, 2020. For inclusion, participants must have elevated blood pressure and belong
- to a sociodemographic group with known disparities in hypertension. We also tracked
- 25 specific characteristics of each intervention. Out of the eight articles that met our eligibility
- criteria for inclusion, five were published in 2018 to 2020. Only four demonstrated a
- significant reduction in BP and all those interventions incorporated care teams. Despite some
   evidence of the effectiveness of mHealth interventions for improving BP control among
- vulnerable groups, more effective interventions are needed, and the quality of studies is
- 30 overall low. Further research is needed to find the most effective ways to engage diverse
- 31 communities with mHealth solutions to improve BP control.

# 32 Keywords

Hypertension, disparities, health IT, mHealth, public health, blood pressure, cardiovasculardisease

## **Funding Details**

- 36 The research reported in this publication was supported by Patient-Centered Outcomes
- 37 Research Institute (PCORI) [PaCR-2017C2-8153]. The content is solely the responsibility of
- the authors and does not necessarily represent the official views of BPTrack/PCORI

## **39 Competing Interests**

- 40 Mark J. Pletcher, MD, MPH has received research grants from the Patient-Centered
- 41 Outcomes Research Institute (PCORI). All the other authors declare that there is no conflict42 of interest regarding the publication of this paper.

## 43 Data Availability

The data used to support the findings of this study are available from the correspondingauthor upon request.

## 46 Introduction

- 47 Uncontrolled blood pressure (BP) causes over 450,000 deaths per year in the United States
- 48 (US), making it a leading preventable cause of death.<sup>1,2</sup> While national data indicate that BP
- 49 control rates in the U.S. have improved over time, from approximately 30% in the early
- 50 1990's to 50% in more recent years,  $^{3,4}$  a recent study published in the Journal of the
- 51 American Medical Association revealed that HTN control has declined to 43.7% in 2017-
- 52 2019, and further among minoritized groups.<sup>3</sup> Further, race/ethnic and socioeconomic

- 53 disparities exist, with African American (AA) individuals and those with low-income status
- 54 being at higher risk for uncontrolled HTN.<sup>5</sup> In communities with low socioeconomic and
- resource, the adverse cardiovascular outcomes of HTN and challenges of self-management
- 56 are more severe due to social determinants such as low health literacy, lack of access to 57 quality health are and lack of trust in health are professionals and institutions  $^{6}$
- 57 quality health care, and lack of trust in health care professionals and institutions.<sup>6</sup>

58 A growing body of evidence supports the use of mobile health (mHealth) interventions for health promotion, behavior change, diagnosis, and self-management of risk factors for 59 chronic HTN. MHealth can be defined as "medical and public health practice supported by 60 mobile devices such as mobile phones, patient monitoring devices, personal digital assistants, 61 and other wireless devices".<sup>7,8</sup> It is estimated that more than 90% of U.S. adults own a mobile 62 phone, including 83% AA and 76% of individuals with a low with low-income status, and 63 64 approximately 85% have a smartphone.<sup>9</sup> The use of mHealth interventions is increasing substantially in the general population given the near ubiquity of smartphone and mobile 65 health technologies in all segments of society.<sup>10</sup> The integration of mHealth technology (i.e. 66 home BP monitoring devices and smartphone apps) with electronic health record (EHR) data 67 68 has the potential to provide a major mechanism for interventions for BP management. It is becoming increasingly feasible to help patients self-manage their HTN remotely, allow 69 70 patients to engage and benefit from the comfort of their home environments and 71 communities. Self-management tools are designed to facilitate autonomy in self-

- 72 management, augment patient/clinician collaboration, and to enhance patient
- 73 empowerment.<sup>11</sup>
- 74 While mHealth has been shown to be effective in reducing CVD risk for affluent and well-
- resourced patient populations<sup>12,13</sup>, it is unclear how effective these interventions are among
- vulnerable populations, given existing health and
- healthcare disparities. Several studies provide evidence of the positive impact of mHealth on
- 78 patient adherence with HTN medication regimens.<sup>14</sup> and there is limited evidence to support
- 79 the potential for mHealth to improve HTN outcomes among vulnerable populations, albeit
- 80 the evidence is limited in part to a dearth of interventions specifically targeted to these
- populations. The objective of this study is to describe the characteristics of mHealth
   interventions and to examine whether these interventions are effective for reducing systolic
- and/ or diastolic blood pressure for socioeconomically vulnerable populations (e.g.
- socioeconomic or race/ethnic groups shown to have higher prevalence of hypertension).

## 85 Materials and Methods

### 86 Review Design and Study Selection

- 87 We conducted a systematic review to assess effectiveness of mHealth interventions for BP
- 88 management among individuals with elevated BP in socioeconomically vulnerable
- 89 populations. This review was registered in advance on PROSPERO under study number
- 90 CRD42020169115.<sup>15</sup> We followed the Preferred Reporting Items for Systematic Reviews and
- 91 Meta-Analyses (PRISMA) guidelines for conducting and reporting items for systematic
- 92 reviews.<sup>16</sup>
- 93 We used the PICOS terminology to frame this work. Participants are those with suboptimal
- 94 BP who belong to a socioeconomic group with known disparities in hypertension.
- 95 Interventions of interest are experimental or quasi-experimental mHealth intervention studies

- 96 to reduce BP. The main comparators are usual care or other non-mHealth interventions for
- 97 BP management. The primary outcome of interest is reduction in systolic and/or diastolic BP.

#### 98 **Search Strategy**

99 We searched the following databases for primary studies: MEDLINE® via PubMed,

- PsychInfo, CINAHL® and EMBASE from January 1, 2009, through December 31, 2020. We 100
- limited the search to studies occurring after 2009 given the significant advances in mHealth 101
- technology over the past decade. We developed a search strategy for MEDLINE, accessed 102
- via PubMed®, based on medical subject headings (MeSH®) terms and text words of key 103
- 104 articles that we identified a priori (Appendix 1). Our basic search concepts were "mHealth AND hypertension". We first identified potentially eligible studies based on title and abstract. 105
- 106 One reviewer (KMJA) reviewed the titles and abstracts based on pre-specified
- 107 inclusion/exclusion criteria. Two reviewers (KMJA and YL) independently reviewed the
- 108 papers identified for full text review using a standardized data extraction form electronically
- entered into a web-based survey tool (Appendix 2). The full text of the final studies were then 109
- 110 reviewed by a third researcher (MP). All discrepancies were resolved by consensus.

#### 111 **Study Selection**

- Study Characteristics. We included interventions that assessed BP self-management using 112
- mHealth in the U.S., Canada, Western Europe or Australia for hypertension management in 113
- our target population as defined below. Studies were included if they were of experimental or 114
- 115 quasi-experimental design, assessed the primary outcome of reduction in systolic and/or
- 116 diastolic BP at least 3 months post-baseline and were published in English. Studies were
- excluded if the primary outcome was specifically related to ocular hypertension or pulmonary 117
- 118 hypertension. Studies with a primary outcome of medication adherence were excluded.
- 119 Studies that were non-experimental in design were excluded, as were studies published only
- 120 as abstracts.
- Target population. Adults (age 18+) with evidence of elevated BP at baseline (i.e. 121
- documented evidence of systolic BP  $\geq$  130 mmHg and/or diastolic BP  $\geq$ 80 mmHg) and 122
- 123 meeting criteria for socioeconomic and racial/ethnic vulnerability relative to bearing
- disproportionate risk for uncontrolled HTN.<sup>17</sup> Studies were included if study participants had 124
- < 50% non-Hispanic White, with > 50% high school education or less, with > 50% Medicaid 125
- or > 50% annual household income < \$50K, and/or a primarily and explicitly defined rural 126
- 127 population. Studies were excluded if the patient population included individuals with a life-
- threatening co-morbid illness (i.e. cancer diagnosis, end stage renal or liver disease) or 128
- 129 pregnant women.
- Intervention Inclusion/Exclusion. We include technology-enabled or enhanced interventions 130
- 131 that specifically utilize mHealth. The Global Observatory for eHealth of the World Health
- 132 Organization defines mHealth as "medical and public health practice supported by mobile
- devices, such as mobile phones, patient monitoring devices, personal digital assistants, and 133
- other wireless devices",<sup>18</sup> or the use of these technologies for health services and 134
- information.<sup>19</sup> Given this definition, eligible interventions must include wearables and/or 135
- 136 devices connected to an app, mobile site and/or mobile internet via wireless connection (e.g.
- 137 Wi-Fi, blue tooth etc.). The intervention must be intended to reduce systolic and/or diastolic
- 138 BP as the primary outcome of interest. Additionally, the intervention must be remote (i.e. 139

- technology outside of the clinic setting), but may include a clinic-based component. We also
- excluded studies with interventions requiring a surgical or invasive component (i.e. implantedor internal BP monitor).

#### 143 Data Extraction and Quality (Risk of Bias) Assessment

- 144 Data were systematically extracted and summarized. We reported study characteristics and
- 145 intervention characteristics, using categories to describe components of included studies to
- 146 facilitate cross-study comparisons. Primary outcomes were reported for all studies.
- 147 Secondary outcomes (i.e. medication adherence) were reported for studies that included these
- 148 outcomes using the metric utilized by the original study.
- All three researchers (KMJA, YL and MP) independently assessed the risk of bias of the
- 150 eight included studies using the Cochrane Risk of Bias tool. The specific domains include
- 151 random sequence generation, allocation concealment, blinding, incomplete outcome data,
- selective reporting, and other source of bias. Any disagreement will be resolved by discussion
- 153 between the three reviewers.

#### 154 **Results**

#### 155 Identification of Studies and Study Selection

- 156 We identified 2,574 articles through the literature search. After excluding duplicates, 2,023
- 157 articles were screened for inclusion based on title and abstract. Of these, 255 abstracts were
- review by one research (KJA) to identify manuscripts requiring a full text review. Two
- 159 researchers (KJA & YFZ) independently assessed 74 full-text papers for eligibility and both
- authors agreed to exclude 66 articles based on the established protocol and criteria. The
- 161 remaining 8 articles were identified as meeting the eligibility criteria for inclusion and were
- then reviewed by a third researcher (MP) for confirmation. Reasons for exclusion of the 66
- 163 full-text articles are indicated by the PRISMA diagram (Figure 1).





165

Figure 1: PRISMA Diagram

#### 167 Study Characteristics, Design and Setting

168 Characteristics of the eight studies are presented in Table 1. Of the eight studies identified for 169 inclusion, six were published since 2017, six were conducted in the United States, one in the 170 United Kingdom<sup>20</sup> and one in Canada.<sup>21</sup> All eight studies were randomized control trials with 171 follow-up ranging from 3 to 12 months. Half of the studies compared the mHealth 172 intervention to usual care<sup>20,22-24</sup>, three used an enhanced usual/standard care group and one 173 involved a passive intervention as the comparison group.<sup>21</sup>

174	Table 1: Study Design, Quality, and Participant Characteristics								
Author and Year	Location	Duration	Design	Sample size (N)	Age (mean)	Racial/Ethnic Minority (%)	Sex	SES	Baseline BP
Schroeder et al. 2020	Albuquerque, New Mexico	12-mo	RCT Arm 1 (n=148): IVR-T Arm 2 (n=147): Usual Care	295	53.4 <u>+</u> 11.3	25.1% AI/AN 4.8% Non-Hispanic Black 51.9% Hispanic 14.6% Non-Hispanic White 3.7% Other	40.3% Male	60.3% Annual Household Income <\$25K/Year 28.1% Unemployed 33.6% food insecurity 48.3% Enrolled in SNAP 53.6% Not enough money for utilities	SBP: 133.6 (19.5) mmHg DBP: 81.5 (12.6) mmHg
Still et al, 2020	Cleveland, Ohio	3-mo	RCT Arm 1 (n = 30): COACHMAN intervention Arm 2 (n = 30): Enhanced Usual Care (EUC)	60	59.5 <u>+</u> 8.9	100% AA	25% Male	51.7% unemployed	Intervention: SBP: 156.7 $\pm$ 9.5 mmHg DBP: 90.5 $\pm$ 14.7 mmHg Control: SBP: 152.2 $\pm$ 12.2 mmHg DBP: 88.1 $\pm$ 13 mmHg
Chandler et al, 2019 **	South Carolina	9-mo	RCT Arm 1 (n=26): Smartphone Med Adherence Stops Hypertension (SMASH) Intervention Arm 2 (n=28): Enhanced standard Care (ESC)	54	46.5 <u>+</u> 9.9	100% Hispanic	61% male	72% High School or less 91% Income ≤\$50k/year	SBP: 151.5 mmHg DBP: 85.7 mmHg
Skolarus et al, 2018	Flint, Michigan	6-mo	RCT Arm 1 (n=46): Usual Care Arm 2 (n=48): Text messages	94	58 <u>+</u> 9.8	97% African American 3% Other	3% Male	29% Medicaid or Uninsured 19% Low health literacy 46% food insecurity	Intervention: SBP: 160.7 (23.6) DBP: 99.0 (11.8) Control: SBP: 162.2 (20.5) DBP: 99.2 (17.8)
Tobe et al, 2018	6 different communities in 3 provinces of Canada.	12-mo	RCT Arm 1 (n=71): Active intervention Arm 2 (n=71): Passive intervention	142	48.7 ± 12.8 (Active) and 49.1 ± 13.1 (Passive)	100% Canadian Indigenous	51% male	First Nations populations living on reservations in six different communities in three provinces of Canada	Active Intervention: SBP: $143 \pm 12 \text{ mmHg}$ DBP: $84 \pm 12 \text{ mmHg}$ Passive Intervention SBP: $145 \pm 16 \text{ mmHg}$ DBP: $86 \pm 10 \text{ mmHg}$
Frias et al, 2017 **	California and Colorado	12-WK	RCT Arm 1 (n = 40): Digital Medicine Offering (DMO) - 4 weeks	109	57.8 (SE 1.1; Combined DMO) and 61.6 (SE 1.7; UC)	15.6% African American 46.8% Hispanic 66% Caucasian	50% Male	31% High School or less 57% Income <u>≤</u> \$20k/year	Combined DMO SBP: 149.3 (1.5) DBP: 86.2 (3.2) Usual Care

Table 1: Study Design Quality and Participant Characteristics

			Arm 2 (n = 40: DMO-12 weeks Arm 3 (n = 29): Usual Care			13.8% Asian			SBP: 155.4 DBP: 83.9
Davidson et al, 2015 **	South Carolina	6-mo	RCT Arm 1 (n = 18): Smartphone Med Adherence Stops Hypertension (SMASH) Intervention Arm 2 (n = 20): Enhanced Standard Care (ESC)	38	$47.5 \pm 11.8$ (SMASH) and $48.45 \pm 11.32$ (ESC)	52.6 % African American 47.4% Hispanic	40% Male	58% High School or less 68% Income <u>&lt;</u> \$50k/year 21% Unemployed	SBP: ~ 156 mmHg (Fig 1) DBP: ~ 89mmHg (Fig 2)
McManus et al, 2010 **	24 general practices in the UK	12-mo	RCT Arm 1 (n = 234): Self- management intervention Arm 2 (n = 246): Usual Care	480	66.4 <u>+</u> 9	96% White 1.5% Black 2% Asian 0.5% Other	47% Male	Subgroup analysis for low vs high Index of multiple deprivation (IMD) 2007 score	Intervention SBP: 152·1 (150·6 to 153·6) DBP: 85·0 (83·9 to 86·1) Control SBP: 151·8 (150·3 to 153·3) DBP: 84·5 (83·3 to 85·7)

176 **Participant characteristics.** The number of participants in a given study ranged between 38

and 480 individuals. For three studies, at least 50% of participants were male. Among the
 studies, three<sup>23,25,26</sup> had more than 50% Non-Hispanic Black participants. One study included

only Hispanic participants<sup>27</sup> and another included only Canadian Indigenous groups.<sup>21</sup>. In

four studies<sup>22,24,25,27</sup> at least half of the participants had an annual income of  $\leq$  \$50K. One

181 study<sup>20</sup> conducted an a priori secondary analysis for low vs high scores for the Index of

182 Multiple Deprivation. All but one study<sup>24</sup> included participants with a baseline BP in the

183 Hypertension Stage 2 range (SBP  $\ge$  140 mmHg and/or diastolic DBP >90 mmHg).<sup>17</sup>

#### 184 Intervention Characteristics

185 We examined mHealth intervention characteristics across the eight included studies (Table

186 2). The eight studies included seven unique interventions, given that two studies  $^{25,27}$  tested

187 the same intervention (i.e. Smartphone Medication Adherence Stops Hypertension

188 [SMASH]). Five interventions were developed with direct involvement from members of a

targeted vulnerable community.<sup>21,23-27</sup> More than half (n = 4; 57%) of the interventions

190 involved the use of a smartphone and/or smartphone application (app).<sup>21,22,25-27</sup> Five

interventions (71%) required remote self-monitoring with an automated sphygmomanometer

192 (arm cuff).<sup>20,21,23,25-27</sup> While one study<sup>24</sup> did not require use of an automated

sphygmomanometer, the option was offered and 98% of participants did use one. One study<sup>22</sup>

194 utilized an ingestible sensor placed in a pill, with a wearable sensor patch intended to

195 promote medication adherence. Three interventions offered educational content.<sup>21,24,26</sup> Three

196 interventions used SMS and text  $messaging^{21,23,25,27}$  to deliver tailored motivational messages,

197 educational content and /or adherence reminders via mobile phone. Three offered

198 visualizations for self-monitored BP metrics and longitudinal trends, adherence and tracking

199 of other health behaviors.<sup>20,22,25,27</sup> Most interventions  $(n = 5; 71\%)^{20-22,25-27}$  involved a

clinical care team, which received transmission of data and/or provided supplemental
 counseling.<sup>26</sup>

### 202 Intervention Effectiveness / Results of Individual Studies

Four studies<sup>20,22,25,27</sup> (including three different interventions) demonstrated a significant 203 204 reduction in mean SBP and/or DBP for treatment vs comparison group participants (Table 1). Davidson et al (2015) and Chandler et al (2019) tested the SMASH intervention whereby 205 adult participant were randomly assigned to either the SMASH group or the Enhanced 206 207 standard care (ESC) group. The intervention was tested in two randomized controlled trials, one largely composed of low socioeconomic status (SES) Hispanic adults  $(n = 54)^{27}$  and the 208 other with low SES Hispanic and AA adults (n = 38, 53% AA and 47% Hispanic,).<sup>25</sup> The 209 210 intervention led to a reduction of the SBP in the SMASH group. The SMASH program involves a smartphone app to improve BP medication adherence as well as Bluetooth-enabled 211 212 automated BP device. Participants were asked to measure their BP using the device and app every three days. It also facilitates timely patient-provider communication and included 213 tailored reinforcement/motivational messages via SMS. The development of the intervention 214 was guided by Self Determination Theory<sup>28,29</sup> and aimed to increase autonomous motivation 215 by linking participants' behavioral changes to their values, beliefs and goals. Messages are 216 217 based upon participant responses to a branch logic questionnaire that identified individual values, beliefs and short/long-term goals. The 600+ messages were developed using 218 219 formative research methods among the target population (i.e. Hispanic adults with 220 hypertension). The intervention also utilized the global systems for mobile electronic tray

- 221 Maya (MedMinder, Inc., Newton, MA, USA), which provided a series of reminder signals to
- take medications. The data was shared with the care team to inform clinical care.

#### Table 2: . Intervention Features and Components

Study	Control	Tech Platform				Intervention Component				
			HTN Edu	BP monitoring	Med reminder	Equipment provision	Technology Training	Lifestyle advice	Human Coaching	Other
Schroeder et al. 2020	Usual Care	Phone: SMS or IVT-T	Х	X	Х	X 98% received an optional Automated BP sphygmomanometer (arm cuff) – no data transmission		Х	X	Х
Still et al, 2020	Enhanced Usual Care: - Printed educational materials on HTN management - Access to one web-based education session on self- monitoring BP Automated BP sphygmomanometer (arm cuff) no data transmission	Web-based App	Х	Х	х	X Bluetooth-enabled Automated BP sphygmomanometer (arm cuff) – no data transmission			х	
Chandler et al. 2019	<ul> <li>no data transmission</li> <li>Enhanced standard Care (ESC):</li> <li>participants received text</li> <li>messages including links to</li> <li>PDFs and brief video clips</li> <li>containing healthy lifestyle tips</li> <li>for attention control</li> </ul>	Арр	Х	Х		X Bluetooth-enabled automated BP sphygmomanometer (arm cuff)	Х	Х	Х	Х
Skolarus et al. 2018	Usual Care	SMS		Х		X Automated BP sphygmomanometer (arm	Х		Х	
Tobe et al. 2018	Passive Intervention Health behaviors SMS alone (not HTN specific)	SMS	Х	Х		X Bluetooth-enabled automated BP sphysmomanometer (arm cuff)			Х	Х
Frias et al. 2017	Usual Care	App Web Portal		Х	Х	-Wearable sensor ja a placebo pill				Х
Davidson et al. 2015	Enhanced standard Care (ESC): participants received text messages including links to PDFs and brief video clips containing healthy lifestyle tips for attention control	Арр	Х	Х		X Bluetooth-enabled automated BP sphygmomanometer (arm cuff)	Х	Х	Х	Х
McManus et al. 2010	Usual Care	Web Based		Х		X Automated BP sphygmomanometer (arm cuff)	Х			
						I-Modem for data transmission				

225 Frias et al (2017) conducted a three-arm randomized controlled trial to test the effectiveness 226 of a digital medicine offering (DMO) among low SES adults with both type 2 diabetes and 227 hypertension (n = 109) and found at 4 weeks compared to usual care. The intervention 228 consisted of the use of an ingestible sensor co-capsulated with antihypertensive medication 229 and transmitting data to an external sensor patch for medication adherence tracking. 230 Participants used DMO (includes digital medicines, the wearable sensor patch, and the 231 mobile device app) for 4 or 12 weeks (treatment groups 1 and 2 respectively) or received usual care (treatment group 3). DMO reports were provided to clinicians to guide decision 232 233 making for medication titration. While the trial was 12-weeks, the primary outcome was 234 mean change in SBP at 4 weeks and was found to be significantly reduced in both treatment 235 arms compared to usual care (Table 1) and maintained at 12 weeks. Also of note, providers 236 taking care of a patient who was randomized to DMO intervention made approximately 3

times more medical decisions per participant compared to usual care.

McManus et al (2010) RCT (n = 480) tested the telemonitoring and self-management in the 238 Control of Hypertension (TASMINH2) intervention and found change in mean SBP between 239 240 baseline 6 and 12 months (SBP decreased by 17.6 mm Hg in the self-management group and by 12.2 mm Hg in the control group). The TASMINH2 intervention combined self-241 management of BP, self-titration of antihypertensive medications combined with 242 243 telemonitoring of home BP measurements by the care team. Monthly summaries of the self-244 management data were sent to the clinical team for review and use in informing clinical care. 245 While the intervention was web-based, it involved the passive transmission of data from the 246 automated sphygmomanometer via i-Modem, inserted into a home electrical outlet. The analysis included a priori-defined subgroup analysis among those with low vs high Index of 247 248 multiple deprivation (IMD) 2007 score. The overall reduction in SBP was greater for 249 participants with low IMD compared with participants with high IMD 2007 at both 6 and 12 250 months (-0.4 mm Hg; 95% CI -5.9 to 5.2, p=0.05and 1.6 mm Hg; 95% CI -4.4 to 7.6, p=0.08 respectively). The remaining four studies<sup>21,23,24,26</sup> did not demonstrate a significant 251 252 reduction in SBP and/or DBP for the treatment vs comparison group participants. Schroeder et al (2020), tested the impact of an interactive voice response and text message (IVR-T) 253 254 based intervention, compared with usual care, to deliver automated appointment and medication refill reminders as well as weekly culturally tailored (i.e. AI/NA) motivational 255 256 messages to encourage self-management. The authors speculate that the null findings may in 257 part be due to study design and a large proportion of participants with hypertension being in 258 control at baseline. Both the Skolarus et al (2018) and Still et al (2020) interventions were 259 developed in collaboration with direct involvement from members of the African American 260 community, using the principles of community-based participatory research. One intervention<sup>23</sup> consisted of prompted remote BP self-monitoring, tailored text-messages that 261 262 are responsive to monitored data as well as both tailored and generic automated textmessages to promote healthy behaviors. The authors speculate that small sample size and 263 low-intensity of the intervention may have contributed to null results. The other 264 intervention<sup>30</sup> combined self-directed web-based hypertension education, remote self-265 monitoring and app-supported medication management along with up to 4 patient-initiated, 266 informal nurse counseling. They speculate that the provision of home BP self-monitoring 267 268 devices to both groups could have resulted in greater awareness and behavior change for all study participants. Finally, Tobe et al (2019) tested a SMS text-based intervention among 269 270 members of the Canadian Indigenous Groups community with hypertension. The intervention 271 consisted of "active" messages to promote BP self-management with "passive" messages to 272 promote generic healthy lifestyle behaviors, compared to passive alone.

#### 273 Strength of Body of Evidence, Risk of Bias and Quality of Studies

274 A summary of study quality, assessed via the Cochrane Risk of Bias Tool, is presented in Table 4. No studies that met the inclusion criteria were excluded from the review on the basis 275 of quality. One<sup>21</sup> of the 8 studies was rated high risk for both incomplete outcome data and 276 selective outcome reporting. The risk of bias for these domains for the other studies was 277 either unknown<sup>23,26</sup> or low<sup>20,22,24,27,31</sup>. There was high or unknown risk of bias due to blinding 278 participants & personnel for all of the studies. 279

280

Table 4: Study Quality Assessment via Cochrane Risk of Bias Tool

Study Information	Random Sequence Generation	Allocation Concealment	Blinding Participants & Personnel	Blinded outcome assessment	Incomplete Outcome Data	Selective Reporting	Other Source of Bias
Schroeder et al, 2020	Unknown	Unknown	High	Low	Low	Low	Low
Still et al, 2020	Low	Unknown	High	High	Unknown	Low	Low
Chandler et al, 2019	Unknown	Unknown	Unknown	Unknown	Low	Low	Unknown
Skolarus et al, 2018	Low	Unknown	High	Low	Unknown	Unknown	Unknown
Tobe et al, 2018	Low	Low	High	High	High	High	Unknown
Frias et al, 2017	Low	Low	High	High	Low	Low	Unknown
Davidson et al, 2015	Unknown	Unknown	Unknown	Unknown	Low	Low	Unknown
McManus et al, 2010	Low	High	High	High	Low	Low	Unknown

#### 281

#### **Discussion** 282

283 In this systematic review we focused on mHealth interventions for BP reduction among individuals with hypertension and belonging to socioeconomically vulnerable and high-risk 284 populations. We identified eight trials that met our eligibility criteria for inclusion. Four of 285 286 these studies, which incorporated care team impact, demonstrated a statistically significant reduction in systolic BP. 287

While there have been several related systematic reviews conducted in recent years<sup>32-39</sup>, our 288

review includes relatively recent literature, where five of the eight studies included were 289

published in 2018 to 2020. One other recent review by Khoong et al.<sup>40</sup> examined the impact 290

of mobile health strategies for BP self-management on BP outcomes but the search was 291

limited to studies conducted prior to July 2019 and, thus, does not include several of those we 292

- have identified.<sup>21,22,24,26,27</sup> Among the main findings was a need for increased diversity in 293
- 294 clinical research studies as well as the use of implementation science frameworks to facilitate
- 295 comparison between different multi-modal studies. Given the rapidly evolving technology, 296 frequent updates to reviews are justified to keep pace with these advancements. Our review
- intentionally uses a broader definition of mHealth interventions for BP, where prior reviews
- 297 have limited focus only on smartphone apps<sup>32,36</sup> and/or SMS interventions<sup>34</sup> Despite 298

persistent disparities, there remains limited evidence to identify effective mHealth strategiesthat will benefit groups that bear a disproportionate burden of hypertension risk and its

**301** related sequalae.<sup>41</sup>

Overall, prior systematic reviews found mixed evidence for the effectiveness of mHealth 302 interventions for hypertension management. A recent systematic review and meta-analysis by 303 304 Li et al. (2020) aimed to measure the effectiveness of mHealth in improving the selfmanagement of hypertension for adults and found a greater reduction in both SBP and DBP 305 in the mHealth intervention groups compared with control groups, -3.78 mm Hg (P<.001; 306 95% CI -4.67 to -2.89) and -1.57 mm Hg (P<.001; 95% CI -2.28 to -0.86), respectively. 307 308 They found that high intensity of medication reminders, user-driven designs with customized 309 2-way communication between patients and physicians and multifaceted functions (i.e. SMS 310 text messaging, linking BP monitoring devices to a Web-based system, apps etc.) were 311 associated with effectiveness. In a meta-analysis of randomized controlled trials testing 312 interactive mHealth interventions for BP management in adults (total n = 4271 participants), Lu et al (2019) found that the interventions were associated with significant changes in 313 314 systolic BP and diastolic BP of -3.85 mmHg and -2.19 mm Hg respectively. While they found evidence of effectiveness, there was no reporting of sociodemographic characteristics 315

316 of participants and only one study included<sup>22</sup> was also included in the present review.

Consistent with prior reviews, a common element among the effective interventions in our 317 review seemed to be intentional involvement and communication with the care team, aimed 318 at informing clinical decision making and medication titration. The four interventions with 319 320 null results did not include a formal mechanism for information sharing with the care team and were, in general, lower intensity (i.e. no care team involvement; passive engagement) in 321 322 comparison to the SMASH, DMO and TASMINH2 interventions. Some early studies in 323 home-based telemonitoring of BP, where remote self-monitored data was shared with the care team, resulted in under treatment and worse outcomes.<sup>42-44</sup> More recent evidence 324 suggests benefit when clinical guidelines are adjusted to recommend lower targets for home 325 readings.<sup>45,46</sup> The SMASH intervention<sup>25,27</sup> involved the generation of a biweekly report from 326 self-monitored BP data that was used to inform clinical care and incorporated commonly 327 328 available, nearly ubiquitous technologies. It is especially promising given that the results were replicated in a second study, though both studies were small (n < 100) and potential for 329 scalability is unclear. The Frias et al (2017) intervention used an ingestible sensor co-330 331 capsulated with antihypertensive medication, which is not a commonly available or widely 332 used technology. The authors did not report cost data and it is unclear how feasible it would be to scale up the intervention. Additionally, the authors reported some incidence of 333 334 gastrointestinal related adverse events, raising questions of safety and acceptability in a 335 broader context. It is important to note that the TASMINH2 study was conducted only in the 336 United Kingdom and was found effective among a group identified as low SES but in the context of socialized medicine. Given this, there may be differences when deploying among 337 338 socioeconomically disadvantaged groups in the U.S.

While health information technology has been recognized as a potentially powerful tool in addressing racial/ethnic disparities among Black communities, it is recognized that high quality research to improve the scalability and sustainability of culturally appropriate interventions is needed.<sup>47</sup> Further, deficiencies in existing interventions that do not promote equitable outcomes must be identified and mitigated.<sup>48</sup> While community-based approaches, such as barbershop and faith-based programs, have shown promise<sup>47,49</sup>, both studies in our review<sup>23,30</sup> which incorporated these types of approaches were not effective for reducing BP.

This could in part be due to limitations in study design (i.e. insufficient power) and also dueto the low intensity of the mHealth interventions themselves.

Several other studies exploring mHealth interventions specifically among socioeconomically 348 vulnerable adults were identified in our review or prior systematic reviews but did not meet 349 our inclusion criteria and are worth noting. Buis et al  $(2017)^{14}$  tested daily, automated text 350 351 reminders sent at individually tailored times, among Black adults with uncontrolled hypertension and did not find significant differences in BP outcomes. This study was 352 excluded due to limited follow- up. Lewinski et al (2019)<sup>50</sup> recruited patients of low 353 socioeconomic status from a federally qualified health center with both diabetes and 354 355 uncontrolled hypertension. The intervention consisted of app and text messages and did not 356 result in improved hypertension control and did not include a comparison group. Neither of 357 these studies involved the care team or incorporated medication management. Taber et al (2018)<sup>51</sup> aimed to assess the efficacy of a pharmacist-led, technology-aided, educational 358 intervention and found modest systolic BP reduction among Black participants (-0.86 mmHg 359 per month, p=0.026), which was not evident in non-Blacks (-0.13 mmHg per month, 360 361 p=0.865). This study was excluded due to a lack of comparison group. The findings in these 362 studies are consistent with the potential importance of care team involvement for

363 interventions aimed at reducing disparities in hypertension.

## 364 Conclusions

365 These findings compel the crucial and critical need for innovation and for the development of

366 more effective interventions specifically to improve outcomes among those at the highest risk

and in the most need. These findings also compel the urgent need for those developing

368 mHealth interventions for hypertension control to engage high-risk and disproportionately

burdened populations. Additionally, the evidence suggests that mHealth innovations should

include more clinical decision support as opposed to self-management alone.

## 371 Acknowledgments

We would like to thank Evans Whitaker, MD, MLIS, and academic librarian for UCSFHealth Science Library.

## 374 **Supplementary Materials**

## 375 Supplemental Material #1

Section/topic	#	Checklist item	
TITLE		L	
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT	•		
Structured summary	2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.		3
INTRODUCTION		•	
Rationale	3	Describe the rationale for the review in the context of what is already known.	6-7
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6-7
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	N/A
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	4-5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	8-10
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	8 and Appendix 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	9 and Figure 1
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	10
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	10

Section/topic	#	Checklist item	Reported on page #
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> ) for each meta-analysis.	
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	
Additional analyses	16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.		n/a
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9-10
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8 and Table 1 and Table 2
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	10-11
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	7-8 and table 3
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	11
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	16
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	14, 17 and Table 4
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	16
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	18-19
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future	19-20

#	Checklist item	Reported on page #
	research.	
27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	n/a
	# 27	#       Checklist item         research.       research.         27       Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.

380

Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Checklist

### 377 Supplemental Material #3

#### 378 RedCap survey: <u>https://redcap.ucsf.edu/surveys/?s=FR93D3Y8K9</u>

## 379 Supplemental Material #3

Database	Search strategy
MEDLINE® via PubMed	(High blood pressure [tiab] OR Hypertension [tiab] OR Uncontrolled blood pressure [tiab] OR Elevated blood pressure [tiab]) AND (mHealth [tiab] OR smartphone [mh] OR wearable [tiab] OR mobile device [tiab] OR Bluetooth [tiab] OR Wireless [tiab] OR technology [tiab] OR telehealth [tiab] OR telemedicine/methods [mh] OR eHealth [tiab] OR mobile applications*[mh])
CINAHL®	High blood pressure OR Hypertension OR Uncontrolled blood pressure OR Elevated blood pressure [ABSTRACT] AND mHealth OR smartphone [mh] OR wearable OR mobile device OR Bluetooth OR Wireless OR technology OR telehealth OR telemedicine/methods [mh] OR eHealth OR mobile applications*[mh] [ABSTRACT]
PsychInfo	High blood pressure OR Hypertension OR Uncontrolled blood pressure OR Elevated blood pressure [ABSTRACT] AND mHealth OR smartphone [mh] OR wearable OR mobile device OR Bluetooth OR Wireless OR technology OR telehealth OR telemedicine/methods [mh] OR eHealth OR mobile applications*[mh] [ABSTRACT]
EMBASE	High blood pressure OR Hypertension OR Uncontrolled blood pressure OR Elevated blood pressure [TITLE or ABSTRACT] AND mHealth OR smartphone [mh] OR wearable OR mobile device OR Bluetooth OR Wireless OR technology OR telehealth OR telemedicine/methods [mh] OR eHealth OR mobile applications*[mh][TITLE or ABSTRACT]
	Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Checklist

### 381 Supplemental Material #4

Study	Outcomes	Effects
Schroeder et al, 2020	Change in mean SBP at 12 months	No significant differences were found for change in SBP at 12 months
Still et al, 2020	Change in mean SBP and DBP at 3 months	No significant differences were found for change in SBP or DBP at 3 months
Chandler et al, 2019	Change in mean SBP at 6 months	Mean SBP was significantly lower in the SMASH (121.8mmHg) vs ESC groups at 9 months (145.7mmHg) (P<0.01).
Skolarus et al, 2018	Change in mean SBP and DBP at 6 months	Mean SBP and DBP are not significantly lower in the control group $(162.2\pm20.5, 99.2\pm17.8)$ vs intervention group $(160.7\pm23.6, 99.0\pm11.8)$ at 6 months
Tobe et al, 2018	Change in mean SBP and DBP from BL to last 2 months of measurement	No significant differences were found for change in SBP or DBP from BL to final measurement
Frias et al, 2017	Change in mean SBP at week 4	At week 4, combined DMO had a mean change in SBP from baseline of -21.8 (SE 1.5) mm Hg compared to -12.7 (SE 2.8) mm Hg for usual care (combined DMO-usual care: mean -9.1, SE 2.9, 95% CI -14.8 to -3.3 mm Hg; ICC=0; adjusted difference: mean -10.0, SE 3.1, 95% CI -16.1 to -3.9 mm Hg; effect size=0.69
Davidson et al, 2015	Change in mean SBP and DBP at 3 and at 6 months	Mean SBP and DBP are significantly lower in the SMASH group (SBP: $120\pm5$ ; DBP: $71\pm5$ ) vs ESC group (SBP: $145\pm5$ ; DBP: $84\pm5$ ) at 3 months and 6 months (P < 0.001).
McManus et al, 2010	Change in mean SBP at 6 months and 12 months	Overall difference in mean SBP reduction between self-management and usual care was $3.7 \text{ mm Hg}$ (95% CI $0.8-6.6$ ; p= $0.013$ ) at 6 mo and 5.4 mmHg (95% CI $2.4-8.5$ ; p= $0.0004$ ) at 12 mo Difference in mean SBP reduction for low IMD 2007 score ( $5.3 \text{ mm Hg}$ , 95% CI $1.9-8.8$ , at 6 mo; 7.0 mm Hg, $3.5-10.6$ , at 12 mo) vs high IMD 2007 score ( $-0.4 \text{ mm Hg}$ , $-5.9$ to $5.2$ , at 6 mo; $1.6 \text{ mm Hg}$ , $-4.4$ to $7.6$ , at 12 mo; p= $0.05$ and p= $0.08$

Table 3: Study Outcomes and Effects.

#### 384 **References**

- Collaborators GBDRF. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1659-1724.
- Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009;6(4):e1000058.
- Muntner P, Carey RM, Gidding S, et al. Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. Circulation. 2018;137(2):109-118.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138(17):e426-e483.
- Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension Prevalence and Control Among Adults: United States, 2015-2016. NCHS Data Brief. 2017(289):1-8.
- 398<br/>3996.Zha P, Qureshi R, Porter S, et al. Utilizing a Mobile Health Intervention to Manage Hypertension in an Underserved Community.<br/>West J Nurs Res. 2020;42(3):201-209.
- 400<br/>4017.Abebe NA, Capozza KL, Des Jardins TR, et al. Considerations for community-based mHealth initiatives: insights from three<br/>Beacon Communities. J Med Internet Res. 2013;15(10):e221.
- 402 8. WHO Global Observatory for eHealth, & World Health Organization. MHealth: New horizons for health through mobile technologies. Geneva: World Health Organization;2011.
- 404
   9.
   Mobile Fact Sheet. https://www.pewresearch.org/internet/fact-sheet/mobile/. Pew Research Center. 2021. Accessed May 22, 2021.
- 406<br/>40710.Kelli HM, Witbrodt B, Shah A. The Future of Mobile Health Applications and Devices in Cardiovascular Health. Euro Med J<br/>Innov. 2017;2017:92-97.
- 408<br/>40911.Boulos MN, Brewer AC, Karimkhani C, Buller DB, Dellavalle RP. Mobile medical and health apps: state of the art, concerns,<br/>regulatory control and certification. Online J Public Health Inform. 2014;5(3):229.
- 410<br/>41112.Li R, Liang N, Bu F, Hesketh T. The Effectiveness of Self-Management of Hypertension in Adults Using Mobile Health:<br/>Systematic Review and Meta-Analysis. JMIR Mhealth Uhealth. 2020;8(3):e17776.
- 412<br/>41313.Lu X, Yang H, Xia X, et al. Interactive Mobile Health Intervention and Blood Pressure Management in Adults. Hypertension.<br/>2019;74(3):697-704.
- 414<br/>41514.Buis L, Hirzel L, Dawood RM, et al. Text Messaging to Improve Hypertension Medication Adherence in African Americans<br/>From Primary Care and Emergency Department Settings: Results From Two Randomized Feasibility Studies. JMIR Mhealth<br/>Uhealth. 2017;5(2):e9.
- 417<br/>41815.Azar K, Pletcher M, Fontil V, Faulkner M. Effectiveness of mHealth Interventions for Blood Pressure Control Among<br/>Vulnerable Populations: A Systematic Review. PROSPERO.<br/>https://www.crd.york.ac.uk/prospero/display\_record.php?ID=CRD42020169115. Accessed May 22, 2021.
- 420<br/>42116.Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the<br/>PRISMA statement. J Clin Epidemiol. 2009;62(10):1006-1012.
- 422<br/>42317.Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA<br/>Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the<br/>American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol.<br/>2018;71(19):e127-e248.
- 426 18. World Health Organization. mHealth: new horizons for health through mobile technologies Geneva, Switzerland 2011. add website & date accessed (Organization site reference e.g., ISSN International Centre: The ISSN register. http://www.issn.org (2006). Accessed 20 Feb 2007.

- 429 19. Burke LE, Ma J, Azar KM, et al. Current Science on Consumer Use of Mobile Health for Cardiovascular Disease Prevention: A Scientific Statement From the American Heart Association. Circulation. 2015;132(12):1157-1213.
- 431<br/>43220.McManus RJ, Mant J, Bray EP, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a<br/>randomised controlled trial. Lancet. 2010;376(9736):163-172.
- 433 21. Tobe SW, Yeates K, Campbell NRC, et al. Diagnosing hypertension in Indigenous Canadians (DREAM-GLOBAL): A randomized controlled trial to compare the effectiveness of short message service messaging for management of hypertension: Main results. J Clin Hypertens (Greenwich). 2019;21(1):29-36.
- 436
   437
   438
   22. Frias J, Virdi N, Raja P, Kim Y, Savage G, Osterberg L. Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial. J Med Internet Res. 2017;19(7):e246.
- 439 23. Skolarus LE, Cowdery J, Dome M, et al. Reach Out Churches: A Community-Based Participatory Research Pilot Trial to Assess the Feasibility of a Mobile Health Technology Intervention to Reduce Blood Pressure Among African Americans. Health promotion practice. 2018;19(4):495-505.
- 442<br/>44324.Schroeder EB, Moore KR, Manson SM, et al. A randomized clinical trial of an interactive voice response and text message<br/>intervention for individuals with hypertension. Journal of Clinical Hypertension. 2020;22(7):1228-1238.
- 444<br/>44525.Davidson TM, McGillicuddy J, Mueller M, et al. Evaluation of an mHealth Medication Regimen Self-Management Program for<br/>African American and Hispanic Uncontrolled Hypertensives. J Pers Med. 2015;5(4):389-405.
- 446 26. Still CH, Margevicius S, Harwell C, et al. A Community and Technology-Based Approach for Hypertension Self-Management (COACHMAN) to Improve Blood Pressure Control in African Americans: Results from a Pilot Study. Patient Prefer Adherence. 2020;14:2301-2313.
- Chandler J, Sox L, Kellam K, Feder L, Nemeth L, Treiber F. Impact of a Culturally Tailored mHealth Medication Regimen Self-Management Program upon Blood Pressure among Hypertensive Hispanic Adults. Int J Environ Res Public Health. 2019;16(7).
- 451<br/>45228.Ng JY, Ntoumanis N, Thogersen-Ntoumani C, et al. Self-Determination Theory Applied to Health Contexts: A Meta-Analysis.<br/>Perspect Psychol Sci. 2012;7(4):325-340.
- 453<br/>45429.Deci EL, Koestner R, Ryan RM. A meta-analytic review of experiments examining the effects of extrinsic rewards on intrinsic<br/>motivation. Psychol Bull. 1999;125(6):627-668; discussion 692-700.
- 455<br/>45630.Still CH, Margevicius S, Harwell C, et al. A community and technology-based approach for hypertension self-management<br/>(Coachman) to improve blood pressure control in african americans: Results from a pilot study. Patient Preference and<br/>Adherence. 2020;14:2301-2313.
- 458<br/>45931.Davidson TM, McGillicuddy J, Mueller M, et al. Evaluation of an mHealth Medication Regimen Self-Management Program for<br/>African American and Hispanic Uncontrolled Hypertensives. Journal of Personalized Medicine. 2015;5(4):389-405.
- 460<br/>46132.Alessa T, Abdi S, Hawley MS, de Witte L. Mobile Apps to Support the Self-Management of Hypertension: Systematic Review<br/>of Effectiveness, Usability, and User Satisfaction. JMIR Mhealth Uhealth. 2018;6(7):e10723.
- 462<br/>46333.Xiong S, Berkhouse H, Schooler M, et al. Effectiveness of mHealth Interventions in Improving Medication Adherence Among<br/>People with Hypertension: a Systematic Review. Curr Hypertens Rep. 2018;20(10):86.
- 464<br/>46534.Vargas G, Cajita MI, Whitehouse E, Han HR. Use of Short Messaging Service for Hypertension Management: A Systematic<br/>Review. J Cardiovasc Nurs. 2017;32(3):260-270.
- 466<br/>46735.McLean G, Band R, Saunderson K, et al. Digital interventions to promote self-management in adults with hypertension<br/>systematic review and meta-analysis. J Hypertens. 2016;34(4):600-612.
- 468<br/>46936.Mohammadi R, Ayatolahi Tafti M, Hoveidamanesh S, Ghanavati R, Pournik O. Reflection on Mobile Applications for Blood<br/>Pressure Management: A Systematic Review on Potential Effects and Initiatives. Stud Health Technol Inform. 2018;247:306-<br/>310.
- 471<br/>47237.Andre N, Wibawanti R, Siswanto BB. Mobile Phone-Based Intervention in Hypertension Management. Int J Hypertens.<br/>2019;2019:9021017.
- 473<br/>47438.Mileski M, Kruse CS, Catalani J, Haderer T. Adopting Telemedicine for the Self-Management of Hypertension: Systematic<br/>Review. JMIR Med Inform. 2017;5(4):e41.

- 47539.Li R, Liang N, Bu F, Hesketh T. The Effectiveness of Self-Management of Hypertension in Adults Using Mobile Health:<br/>Systematic Review and Meta-Analysis. JMIR mHealth and uHealth. 2020;8(3):e17776.
- 477
   40. Khoong EC, Olazo K, Rivadeneira NA, et al. Mobile health strategies for blood pressure self-management in urban populations with digital barriers: systematic review and meta-analyses. NPJ Digit Med. 2021;4(1):114.
- 479<br/>48041.Doshi R, Aseltine RH, Sabina AB, Graham GN. Interventions to Improve Management of Chronic Conditions Among Racial<br/>and Ethnic Minorities. J Racial Ethn Health Disparities. 2017;4(6):1033-1041.
- 481<br/>48242.Staessen JA, Den Hond E, Celis H, et al. Antihypertensive treatment based on blood pressure measurement at home or in the<br/>physician's office: a randomized controlled trial. JAMA. 2004;291(8):955-964.
- 483 43. Verberk WJ, Kroon AA, Lenders JW, et al. Self-measurement of blood pressure at home reduces the need for antihypertensive drugs: a randomized, controlled trial. Hypertension. 2007;50(6):1019-1025.
- 485<br/>48644.McManus RJ, Mant J, Franssen M, et al. Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration<br/>of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial. Lancet. 2018;391(10124):949-959.
- 487<br/>48845.Stoddart A, Hanley J, Wild S, et al. Telemonitoring-based service redesign for the management of uncontrolled hypertension<br/>(HITS): cost and cost-effectiveness analysis of a randomised controlled trial. BMJ Open. 2013;3(5).
- 489 46. Bray EP, Holder R, Mant J, McManus RJ. Does self-monitoring reduce blood pressure? Meta-analysis with meta-regression of randomized controlled trials. Ann Med. 2010;42(5):371-386.
- 491<br/>49247.Ferdinand DP, Nedunchezhian S, Ferdinand KC. Hypertension in African Americans: Advances in community outreach and<br/>public health approaches. Prog Cardiovasc Dis. 2020;63(1):40-45.
- 493<br/>49448.Zhang X, Hailu B, Tabor DC, et al. Role of Health Information Technology in Addressing Health Disparities: Patient, Clinician,<br/>and System Perspectives. Med Care. 2019;57 Suppl 6 Suppl 2:S115-S120.
- 495<br/>49649.Brewer LC, Hayes SN, Caron AR, et al. Promoting cardiovascular health and wellness among African-Americans: Community<br/>participatory approach to design an innovative mobile-health intervention. PLoS One. 2019;14(8):e0218724.
- 497<br/>49850.Lewinski AA, Patel UD, Diamantidis CJ, et al. Addressing Diabetes and Poorly Controlled Hypertension: Pragmatic mHealth<br/>Self-Management Intervention. J Med Internet Res. 2019;21(4):e12541.
- 49951.Taber DJ, Gebregziabher M, Posadas A, Schaffner C, Egede LE, Baliga PK. Pharmacist-Led, Technology-Assisted Study to500Improve Medication Safety, Cardiovascular Risk Factor Control, and Racial Disparities in Kidney Transplant Recipients. J Am<br/>Coll Clin Pharm. 2018;1(2):81-88.